SI1516628T1
(sl)
*
|
1995-07-27 |
2013-10-30 |
Genentech, Inc. |
Stabilna izotonična liofilizirana proteinska formulacija
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
GB9610992D0
(en)
*
|
1996-05-24 |
1996-07-31 |
Glaxo Group Ltd |
Concentrated antibody preparation
|
EP0852951A1
(de)
*
|
1996-11-19 |
1998-07-15 |
Roche Diagnostics GmbH |
Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
|
CA2292730C
(en)
*
|
1997-06-13 |
2008-09-16 |
Genentech, Inc. |
Stabilized antibody formulation
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
US6991790B1
(en)
|
1997-06-13 |
2006-01-31 |
Genentech, Inc. |
Antibody formulation
|
WO1999055310A1
(en)
|
1998-04-27 |
1999-11-04 |
Altus Biologics Inc. |
Stabilized protein crystals, formulations containing them and methods of making them
|
AU754002B2
(en)
*
|
1998-03-26 |
2002-10-31 |
Merck Sharp & Dohme Corp. |
Formulations for protection of peg-interferon alpha conjugates
|
IL139035A0
(en)
*
|
1998-05-06 |
2001-11-25 |
Genentech Inc |
Protein purification by ion exchange chromatography
|
US20030166525A1
(en)
|
1998-07-23 |
2003-09-04 |
Hoffmann James Arthur |
FSH Formulation
|
CN1053590C
(zh)
*
|
1998-10-19 |
2000-06-21 |
卫生部长春生物制品研究所 |
冻干甲型肝炎减毒活疫苗及其保护剂
|
CA2346996C
(en)
|
1998-10-23 |
2013-11-19 |
Amgen Inc. |
Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
|
EP1157041B1
(en)
|
1999-03-01 |
2005-06-01 |
Genentech, Inc. |
Antibodies for cancer therapy and diagnosis
|
US6914128B1
(en)
|
1999-03-25 |
2005-07-05 |
Abbott Gmbh & Co. Kg |
Human antibodies that bind human IL-12 and methods for producing
|
JP4557098B2
(ja)
*
|
1999-03-31 |
2010-10-06 |
味の素株式会社 |
安定な6−アミジノ−2−ナフチル4−グアニジノベンゾエート酸付加塩製剤ならびにその製造方法
|
EP1180368B1
(en)
*
|
1999-05-31 |
2007-04-18 |
Mitsubishi Chemical Corporation |
Freeze dried hgf preparations
|
CA2376894C
(en)
|
1999-06-12 |
2009-10-20 |
Bitop Gmbh |
Pharmaceutical composition comprising a protein and an ectoine
|
EP2283866B1
(en)
|
1999-06-25 |
2015-02-25 |
Genentech, Inc. |
Methods of treatment using anti-erbb antibody-maytansinoid conjugates
|
NZ531426A
(en)
|
1999-06-25 |
2005-10-28 |
Genentech Inc |
Method of treating cancer wherein the cancer expresses epidermal growth factor receptor comprising administration of humanized anti-ErbB2 antibodies
|
EP1064934A1
(en)
*
|
1999-06-30 |
2001-01-03 |
Applied Research Systems ARS Holding N.V. |
GRF-containing lyophilized pharmaceutical composition
|
PT1210115E
(pt)
|
1999-08-27 |
2009-11-12 |
Genentech Inc |
Dosagens para tratamento com anticorpos anti-erbb2
|
WO2001024763A2
(en)
|
1999-10-01 |
2001-04-12 |
Immunogen, Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
BR0014486A
(pt)
*
|
1999-10-04 |
2002-09-17 |
Chiron Corp |
Composições farmacêuticas contendo polipeptìdeo lìquido estabilizado
|
EP1233784B1
(en)
*
|
1999-12-02 |
2008-07-09 |
Novartis Vaccines and Diagnostics, Inc. |
Compositions and methods for stabilizing biological molecules upon lyophilization
|
JP3884652B2
(ja)
|
1999-12-14 |
2007-02-21 |
サーモ エレクトロン コーポレイション−ポイント オブ ケア エンド ラピッド ダイアグノスティックス |
ポリペプチドおよび抗原の安定化希釈液
|
GB9930882D0
(en)
*
|
1999-12-30 |
2000-02-23 |
Nps Allelix Corp |
GLP-2 formulations
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
US6632979B2
(en)
|
2000-03-16 |
2003-10-14 |
Genentech, Inc. |
Rodent HER2 tumor model
|
KR20030007640A
(ko)
|
2000-05-19 |
2003-01-23 |
제넨테크, 인크. |
ErbB 길항제에 의한 암 치료요법에 대한 효과적인반응의 가능성을 개선시키기 위한 유전자 검출 분석
|
WO2001097858A2
(en)
|
2000-06-20 |
2001-12-27 |
Idec Pharmaceuticals Corporation |
Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
|
EP1314437B1
(en)
|
2000-08-11 |
2014-06-25 |
Chugai Seiyaku Kabushiki Kaisha |
Stabilized antibody-containing preparations
|
CN1592645A
(zh)
|
2000-09-18 |
2005-03-09 |
拜奥根Idec公司 |
使用b细胞耗尽/免疫调节抗体组合治疗自身免疫病的联合疗法
|
CA2423227C
(en)
†
|
2000-10-12 |
2011-11-29 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
US8703126B2
(en)
|
2000-10-12 |
2014-04-22 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
AU2002228771B2
(en)
|
2000-11-02 |
2007-10-25 |
Sloan-Kettering Institute For Cancer Research |
Small molecule compositions for binding to HSP90
|
NZ527284A
(en)
|
2001-01-31 |
2007-03-30 |
Biogen Idec Inc |
Anti-CD23 antibodies for the immunotherapeutic treatment of malignancies including B cell chronic lymphocytic leukaemia
|
US20020159996A1
(en)
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
CN100574803C
(zh)
|
2001-01-31 |
2009-12-30 |
拜奥根Idec公司 |
免疫调节抗体在治疗肿瘤性疾病中的用途
|
JP2004529188A
(ja)
|
2001-05-23 |
2004-09-24 |
スローン − ケッタリング インスティチュート フォー キャンサー リサーチ |
上昇に関連した癌の治療法
|
GB0113179D0
(en)
*
|
2001-05-31 |
2001-07-25 |
Novartis Ag |
Organic compounds
|
CA2385745C
(en)
|
2001-06-08 |
2015-02-17 |
Abbott Laboratories (Bermuda) Ltd. |
Methods of administering anti-tnf.alpha. antibodies
|
DE10133394A1
(de)
*
|
2001-07-13 |
2003-01-30 |
Merck Patent Gmbh |
Flüssige Formulierung enthaltend Cetuximab
|
JP4317010B2
(ja)
*
|
2001-07-25 |
2009-08-19 |
ピーディーエル バイオファーマ,インコーポレイティド |
IgG抗体の安定な凍結乾燥医薬製剤
|
AU2002363339B2
(en)
*
|
2001-11-08 |
2008-02-07 |
Abbvie Biotechnology Ltd |
Stable liquid pharmaceutical formulation of IGG antibodies
|
CN100415769C
(zh)
*
|
2002-02-07 |
2008-09-03 |
中国科学院过程工程研究所 |
寡聚或多聚亚基蛋白质分离纯化的方法
|
CN101721362B
(zh)
|
2002-02-14 |
2018-07-03 |
中外制药株式会社 |
包含抗体的溶液制剂
|
DE10211227A1
(de)
*
|
2002-03-13 |
2003-10-02 |
Aventis Behring Gmbh |
Verfahren zur Rekonstitution von Iyophilisierten Proteinen
|
DK1501856T3
(da)
|
2002-04-10 |
2013-03-25 |
Genentech Inc |
Anti-HER2 antistofvarianter
|
US20060246060A1
(en)
*
|
2002-07-02 |
2006-11-02 |
Nesta Douglas P |
Novel stable formulation
|
PT1585966E
(pt)
|
2002-07-15 |
2012-02-20 |
Hoffmann La Roche |
Tratamento de cancro com o anticorpo anti-erbb2 rhumab 2c4
|
US20040033228A1
(en)
*
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
ES2527616T3
(es)
|
2002-09-11 |
2015-01-27 |
Genentech, Inc. |
Purificación de anticuerpos anti-HER2
|
MY150740A
(en)
|
2002-10-24 |
2014-02-28 |
Abbvie Biotechnology Ltd |
Low dose methods for treating disorders in which tnf? activity is detrimental
|
SI2236154T1
(en)
*
|
2003-02-10 |
2018-08-31 |
Biogen Ma Inc. |
THE FORM OF IMUNOGLOBULIN AND THE METHOD OF ITS PREPARATION
|
US20050142139A1
(en)
*
|
2003-03-21 |
2005-06-30 |
Norbert Schulke |
CD4-IgG2 formulations
|
DK1610822T4
(en)
|
2003-04-02 |
2019-01-14 |
Ares Trading Sa |
Liquid pharmaceutical FSH and LH formulations together with a nonionic surfactant
|
AU2012200957B2
(en)
*
|
2003-04-04 |
2014-10-23 |
Genentech, Inc. |
High concentration antibody and protein formulations
|
KR101208291B1
(ko)
|
2003-04-04 |
2012-12-05 |
노파르티스 아게 |
고농도 항체 및 단백질 제형
|
FR2853551B1
(fr)
*
|
2003-04-09 |
2006-08-04 |
Lab Francais Du Fractionnement |
Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee
|
PL1613350T3
(pl)
|
2003-04-09 |
2009-08-31 |
Genentech Inc |
Leczenie choroby autoimmunologicznej u pacjenta z nieodpowiednią odpowiedzią na leczenie inhibitorem TNFα
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
MX369959B
(es)
|
2003-05-14 |
2019-11-27 |
Immunogen Inc |
Composicion de farmaco conjugado.
|
RS20050885A
(sr)
|
2003-05-30 |
2008-04-04 |
Genentech |
Lečenje sa anti-vegf antitelima
|
BRPI0411276A
(pt)
|
2003-06-05 |
2006-08-01 |
Genentech Inc |
métodos de esgotamento de células b, método de tratamento de neoplasma de células b ou malignidade, método de alìvio de disfunção autoimunológica regulada por células b, composição e artigo industrializado
|
WO2004112826A1
(en)
|
2003-06-20 |
2004-12-29 |
Ares Trading Sa |
Freeze-dried fsh / lh formulations
|
EP1660531A2
(en)
|
2003-08-05 |
2006-05-31 |
Novo Nordisk A/S |
Novel insulin derivatives
|
JP2007504215A
(ja)
|
2003-09-03 |
2007-03-01 |
バイオフォームズ |
生体分子を急速に結晶化するための方法及び装置
|
US8277810B2
(en)
|
2003-11-04 |
2012-10-02 |
Novartis Vaccines & Diagnostics, Inc. |
Antagonist anti-CD40 antibodies
|
ME03330B
(me)
|
2003-11-05 |
2019-10-20 |
Roche Glycart Ag |
Cd20 antitijela sa povećanim afinitetom za vezivanje fc receptora i efektornom funkcijom
|
DE10355251A1
(de)
*
|
2003-11-26 |
2005-06-23 |
Merck Patent Gmbh |
Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
|
WO2005072772A1
(en)
*
|
2004-01-30 |
2005-08-11 |
Suomen Punainen Risti Veripalvelu |
Pharmaceutical compositions
|
WO2005089503A2
(en)
*
|
2004-03-19 |
2005-09-29 |
Progenics Pharmaceuticals, Inc. |
Cd4-igg2 formulations
|
US7319032B2
(en)
|
2004-04-22 |
2008-01-15 |
Medtox |
Non-sugar sweeteners for use in test devices
|
US7723306B2
(en)
|
2004-05-10 |
2010-05-25 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
|
US7611709B2
(en)
|
2004-05-10 |
2009-11-03 |
Boehringer Ingelheim Pharma Gmbh And Co. Kg |
1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
|
US7727962B2
(en)
|
2004-05-10 |
2010-06-01 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Powder comprising new compositions of oligosaccharides and methods for their preparation
|
DE102004022927A1
(de)
*
|
2004-05-10 |
2005-12-15 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
1,4 O-verknüpfte Saccharose-Derivate zur Stabilisierung von Antikörpern oder Antikörper-Derivaten
|
MXPA06014065A
(es)
|
2004-06-01 |
2007-01-31 |
Genentech Inc |
Conjugados de droga-anticuerpo y metodos.
|
WO2006014965A2
(en)
*
|
2004-07-27 |
2006-02-09 |
Human Genome Sciences, Inc. |
Pharmaceutical formulation and process
|
US20060051347A1
(en)
*
|
2004-09-09 |
2006-03-09 |
Winter Charles M |
Process for concentration of antibodies and therapeutic products thereof
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
US7521541B2
(en)
|
2004-09-23 |
2009-04-21 |
Genetech Inc. |
Cysteine engineered antibodies and conjugates
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
WO2006060533A2
(en)
|
2004-12-01 |
2006-06-08 |
Genentech, Inc. |
Conjugates of 1, 8-bis-naphthalimides with an antibody
|
ES2504441T3
(es)
|
2004-12-15 |
2014-10-08 |
Swedish Orphan Biovitrum Ab (Publ) |
Formulaciones terapéuticas del factor de crecimiento de queratinocitos
|
US7449184B2
(en)
|
2005-01-21 |
2008-11-11 |
Genentech, Inc. |
Fixed dosing of HER antibodies
|
CN1313161C
(zh)
*
|
2005-01-27 |
2007-05-02 |
北京大学临床肿瘤学院 |
结直肠癌放射免疫导向手术药物及其制备方法
|
WO2006084030A2
(en)
|
2005-02-01 |
2006-08-10 |
Sloan-Kettering Institute For Cancer Research |
Small-molecule hsp90 inhibitors
|
US9403828B2
(en)
|
2005-02-01 |
2016-08-02 |
Sloan-Kettering Institute For Cancer Research |
Small-molecule Hsp90 inhibitors
|
UA95068C2
(uk)
|
2005-02-07 |
2011-07-11 |
Глікарт Біотехнолоджі Аг |
Антиген-зв'язуюча молекула, яка зв'язує еgfr, вектор, що її кодує, та їх застосування
|
RU2404806C2
(ru)
|
2005-02-23 |
2010-11-27 |
Дженентек, Инк. |
Продление времени до прогрессирования заболевания или продолжительности жизни у онкологических больных с применением ингибиторов димеризации her
|
KR101327270B1
(ko)
*
|
2005-03-25 |
2013-11-08 |
리제네론 파라마큐티칼스 인코포레이티드 |
혈관내피성장인자 길항제 조제물
|
NZ599176A
(en)
|
2005-08-03 |
2014-04-30 |
Immunogen Inc |
Immunoconjugate formulations
|
KR101460932B1
(ko)
|
2005-08-26 |
2014-11-12 |
로슈 글리카트 아게 |
변형된 세포 신호 활성을 가진 개질된 항원 결합 분자
|
EP1951305A1
(en)
*
|
2005-11-22 |
2008-08-06 |
Wyeth a Corporation of the State of Delaware |
Immunoglobulin fusion protein formulations
|
US9309316B2
(en)
|
2005-12-20 |
2016-04-12 |
Bristol-Myers Squibb Company |
Stable subcutaneous protein formulations and uses thereof
|
US10508144B2
(en)
|
2005-12-20 |
2019-12-17 |
Bristol-Myers Squibb Company |
Carbohydrate content of CTLA4 molecules
|
AR058568A1
(es)
|
2005-12-20 |
2008-02-13 |
Bristol Myers Squibb Co |
Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
|
AR058567A1
(es)
|
2005-12-20 |
2008-02-13 |
Bristol Myers Squibb Co |
Formulaciones de proteinas estables
|
CN101389650B
(zh)
|
2005-12-28 |
2012-10-10 |
诺沃-诺迪斯克有限公司 |
包含酰化胰岛素和锌的组合物以及制备所述组合物的方法
|
EP1986612B1
(en)
*
|
2006-02-07 |
2012-09-12 |
Shire Human Genetic Therapies, Inc. |
Stabilized composition of glucocerebrosidase
|
WO2008060645A2
(en)
|
2006-03-21 |
2008-05-22 |
Genentech, Inc. |
Combinatorial therapy involving alpha5beta1 antagonists
|
AU2007227224A1
(en)
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Anti-tumor cell antigen antibody therapeutics
|
BRPI0709726A2
(pt)
|
2006-04-05 |
2011-07-26 |
Abbott Biotechnology Ltd. |
purificaÇço de anticorpo
|
EP2010214A4
(en)
|
2006-04-10 |
2010-06-16 |
Abbott Biotech Ltd |
USES AND COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
|
US9283260B2
(en)
*
|
2006-04-21 |
2016-03-15 |
Amgen Inc. |
Lyophilized therapeutic peptibody formulations
|
AU2011265555B2
(en)
*
|
2006-04-21 |
2016-03-10 |
Amgen Inc. |
Lyophilized therapeutic peptibody formulations
|
US7608261B2
(en)
*
|
2006-06-16 |
2009-10-27 |
Regeneron Pharmacuticals, Inc. |
VEGF antagonist formulations suitable for intravitreal administration
|
AR062223A1
(es)
|
2006-08-09 |
2008-10-22 |
Glycart Biotechnology Ag |
Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
|
CN101199483B
(zh)
*
|
2006-12-14 |
2011-01-26 |
上海中信国健药业股份有限公司 |
一种稳定的抗her2人源化抗体制剂
|
CN101199845B
(zh)
*
|
2006-12-14 |
2012-05-23 |
上海国健生物技术研究院 |
一种稳定的抗IgE人源化单抗制剂
|
JP5419709B2
(ja)
*
|
2007-01-09 |
2014-02-19 |
ワイス・エルエルシー |
抗il−13抗体製剤およびその使用
|
KR20150038227A
(ko)
|
2007-01-16 |
2015-04-08 |
애브비 인코포레이티드 |
건선의 치료방법
|
WO2008101179A2
(en)
*
|
2007-02-16 |
2008-08-21 |
Wyeth |
Use of sucrose to suppress mannitol-induced protein aggregation
|
CL2008000614A1
(es)
|
2007-03-02 |
2008-09-05 |
Genentech Inc F Hoffmann La Ro |
Metodo para tratar un paciente con un tipo de cancer que expresa el receptor her3 a un nivel bajo mediante la administracion de un inhibidor de la dimerizacion de her.
|
WO2008121301A1
(en)
|
2007-03-29 |
2008-10-09 |
Abbott Laboratories |
Crystalline anti-human il-12 antibodies
|
EP2171451A4
(en)
|
2007-06-11 |
2011-12-07 |
Abbott Biotech Ltd |
METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
|
JP5552046B2
(ja)
|
2007-06-13 |
2014-07-16 |
ノボ・ノルデイスク・エー/エス |
インスリン誘導体を含有する薬学的製剤
|
EP2190478B1
(en)
|
2007-08-24 |
2016-03-23 |
Oncotherapy Science, Inc. |
Dkk1 oncogene as therapeutic target for cancer and a diagnosing marker
|
JP2010536366A
(ja)
|
2007-08-24 |
2010-12-02 |
オンコセラピー・サイエンス株式会社 |
肺癌の治療及び診断の標的遺伝子のためのebi3、dlx5、nptx1、及びcdkn3
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
KR20090056543A
(ko)
*
|
2007-11-30 |
2009-06-03 |
주식회사 녹십자 |
B형 간염 바이러스(hbv) 중화 인간 항체를 포함하는약학적 제제
|
US11197916B2
(en)
|
2007-12-28 |
2021-12-14 |
Takeda Pharmaceutical Company Limited |
Lyophilized recombinant VWF formulations
|
MX2010007150A
(es)
|
2007-12-28 |
2010-09-03 |
Baxter Int |
Formulaciones del factor de von-willebrand recombinante.
|
US8557243B2
(en)
|
2008-01-03 |
2013-10-15 |
The Scripps Research Institute |
EFGR antibodies comprising modular recognition domains
|
US8557242B2
(en)
|
2008-01-03 |
2013-10-15 |
The Scripps Research Institute |
ERBB2 antibodies comprising modular recognition domains
|
US8454960B2
(en)
|
2008-01-03 |
2013-06-04 |
The Scripps Research Institute |
Multispecific antibody targeting and multivalency through modular recognition domains
|
DK2769991T3
(en)
|
2008-01-03 |
2018-12-10 |
Scripps Research Inst |
ANTIBODY TARGETING WITH A MODULAR RECOGNITION AREA
|
US8574577B2
(en)
|
2008-01-03 |
2013-11-05 |
The Scripps Research Institute |
VEGF antibodies comprising modular recognition domains
|
ATE548052T1
(de)
|
2008-01-17 |
2012-03-15 |
Philogen Spa |
Kombination aus einem anti-edb-fibronectin- antikörper-il-2-fusionsprotein und einem b-zellen bindenden molekül, b-zellen-vorläufern und/oder deren krebserregendem gegenspieler
|
AR070141A1
(es)
|
2008-01-23 |
2010-03-17 |
Glenmark Pharmaceuticals Sa |
Anticuerpos humanizados especificos para el factor von willebrand
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
ES2759075T3
(es)
|
2008-03-14 |
2020-05-07 |
Biocon Ltd |
Un anticuerpo monoclonal y un método del mismo
|
CY1112212T1
(el)
*
|
2008-04-24 |
2015-12-09 |
Immatics Biotechnologies Gmbh |
Νεα σκευασματα πεπτιδιων που σχετιζονται με ογκους τα οποια συνδεονται σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης i ή ii για εμβολια
|
EP2113253B1
(en)
*
|
2008-04-30 |
2010-03-31 |
Immatics Biotechnologies GmbH |
Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules for vaccines
|
US8093018B2
(en)
|
2008-05-20 |
2012-01-10 |
Otsuka Pharmaceutical Co., Ltd. |
Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
|
EP2303332B1
(en)
|
2008-07-15 |
2014-12-31 |
Genentech, Inc. |
Anthracycline conjugates, process for their preparation and their use as antitumor compounds
|
TW201014605A
(en)
|
2008-09-16 |
2010-04-16 |
Genentech Inc |
Methods for treating progressive multiple sclerosis
|
CA2740919A1
(en)
|
2008-10-21 |
2010-04-29 |
Baxter International Inc. |
Lyophilized recombinant vwf formulations
|
CN105646643A
(zh)
|
2008-10-29 |
2016-06-08 |
阿布林克斯公司 |
单域抗原结合性分子的纯化方法
|
CA2738243C
(en)
*
|
2008-10-29 |
2020-09-29 |
Wyeth Llc |
Formulations of single domain antigen binding molecules
|
JP4959005B2
(ja)
|
2008-10-30 |
2012-06-20 |
ノボ・ノルデイスク・エー/エス |
毎日の注射頻度より少ないインスリン注射での真性糖尿病の治療
|
ES2611337T3
(es)
|
2008-11-22 |
2017-05-08 |
F. Hoffmann-La Roche Ag |
Uso de anticuerpo anti-VEGF en combinación con quimioterapia para tratar cáncer de mama
|
EP2196476A1
(en)
|
2008-12-10 |
2010-06-16 |
Novartis Ag |
Antibody formulation
|
FR2940617B1
(fr)
*
|
2008-12-30 |
2012-04-20 |
Fractionnement Et Des Biotechonologies Lab Franc |
Composition d'immunoglobulines g
|
EP2403874A1
(en)
|
2009-03-06 |
2012-01-11 |
Genentech, Inc. |
Antibody formulation
|
NZ594343A
(en)
|
2009-03-25 |
2013-10-25 |
Genentech Inc |
Novel anti-alpha5beta1 antibodies and uses thereof
|
JP2012518680A
(ja)
|
2009-03-31 |
2012-08-16 |
ロシュ グリクアート アクチェンゲゼルシャフト |
ヒト化抗EGFRIgG1抗体及びイリノテカンによる癌の処置
|
AR075998A1
(es)
|
2009-04-01 |
2011-05-11 |
Genentech Inc |
Tratamiento de trastornos resistentes a insulina.composicion farmaceutica. uso. kit
|
US20100316639A1
(en)
|
2009-06-16 |
2010-12-16 |
Genentech, Inc. |
Biomarkers for igf-1r inhibitor therapy
|
NZ713967A
(en)
|
2009-07-28 |
2017-01-27 |
Shire Human Genetic Therapies |
Compositions and methods for treating gaucher disease
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
CA2771086A1
(en)
|
2009-08-15 |
2011-02-24 |
Genentech, Inc. |
Anti-angiogenesis therapy for the treatment of previously treated breast cancer
|
JP2013504585A
(ja)
|
2009-09-09 |
2013-02-07 |
セントローズ, エルエルシー |
細胞外標的化薬物複合体
|
AR078161A1
(es)
*
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
KR101653471B1
(ko)
|
2009-10-01 |
2016-09-01 |
에프. 호프만-라 로슈 아게 |
다단계 최종 여과
|
CA2781467C
(en)
*
|
2009-11-20 |
2015-10-13 |
Biocon Limited |
Formulations of antibody
|
RU2580038C2
(ru)
|
2009-12-04 |
2016-04-10 |
Дженентек, Инк. |
Мультиспецифические антитела, аналоги антител, композиции и способы
|
MX337432B
(es)
|
2009-12-15 |
2016-03-04 |
Ascendis Pharma As |
Composicion de la hormona del crecimiento seca enlazada transitoriamente a un portador del polimero.
|
KR20120110175A
(ko)
*
|
2009-12-29 |
2012-10-09 |
에프. 호프만-라 로슈 아게 |
항체 제제
|
AR080428A1
(es)
|
2010-01-20 |
2012-04-11 |
Chugai Pharmaceutical Co Ltd |
Formulaciones liquidas estabilizadas contentivas de anticuerpos
|
US20110200595A1
(en)
|
2010-02-18 |
2011-08-18 |
Roche Glycart |
TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
|
EA027915B1
(ru)
|
2010-02-19 |
2017-09-29 |
Кадила Фармасьютикалз Лимитед |
Способ получения композиции убитых клеток, по существу, с сохраненной иммуногенностью
|
EP2539367A2
(en)
|
2010-02-23 |
2013-01-02 |
F. Hoffmann-La Roche AG |
Anti-angiogenesis therapy for the treatment of ovarian cancer
|
MY174760A
(en)
|
2010-03-01 |
2020-05-13 |
Bayer Healthcare Llc |
Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
|
CA2794929C
(en)
*
|
2010-03-01 |
2018-06-05 |
Progenics Pharmaceuticals, Inc. |
Concentrated protein formulations and uses thereof
|
HUE042330T2
(hu)
|
2010-03-31 |
2019-06-28 |
Stabilitech Biopharma Ltd |
Módszer alumínium adjuvánsok és alumíniummal adjuvált vakcinák megóvására
|
DK2898890T3
(da)
|
2010-03-31 |
2019-11-25 |
Stabilitech Biopharma Ltd |
Stabilisering af viruspartikler
|
CA2795047C
(en)
|
2010-03-31 |
2019-04-09 |
Stabilitech Ltd. |
Stabilised liquid formulations
|
MA34225B1
(fr)
*
|
2010-04-27 |
2013-05-02 |
Scil Technology Gmbh |
Préparation stable de mia/cd-rap
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
WO2011153243A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Anti-angiogenesis therapy for treating gastric cancer
|
CA2802756C
(en)
*
|
2010-06-24 |
2021-05-04 |
Genentech, Inc. |
Compositions and methods for stabilizing protein-containing formulations
|
SG186421A1
(en)
*
|
2010-07-02 |
2013-01-30 |
Medimmune Llc |
Antibody formulations
|
US20120100166A1
(en)
|
2010-07-15 |
2012-04-26 |
Zyngenia, Inc. |
Ang-2 Binding Complexes and Uses Thereof
|
US9458509B2
(en)
|
2010-07-22 |
2016-10-04 |
President And Fellows Of Harvard College |
Multiple input biologic classifier circuits for cells
|
US20130177500A1
(en)
|
2010-07-23 |
2013-07-11 |
Trustee Of Boston University |
Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
|
NZ609557A
(en)
*
|
2010-10-06 |
2014-12-24 |
Regeneron Pharma |
Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
|
DK2632478T3
(da)
|
2010-10-27 |
2019-10-07 |
Novo Nordisk As |
Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
|
AR083847A1
(es)
|
2010-11-15 |
2013-03-27 |
Novartis Ag |
Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
|
US9045728B2
(en)
|
2010-12-02 |
2015-06-02 |
Oncolytics Biotech Inc. |
Liquid viral formulations
|
TW201233803A
(en)
|
2010-12-02 |
2012-08-16 |
Oncolytics Biotech Inc |
Lyophilized viral formulations
|
JP5838221B2
(ja)
|
2010-12-21 |
2016-01-06 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
アイソフォーム濃縮抗体調製物及びこれを得る方法
|
CN102028661B
(zh)
*
|
2010-12-31 |
2012-05-23 |
山东新时代药业有限公司 |
聚乙二醇化重组人粒细胞集落刺激因子冻干粉针剂及其制备方法
|
MX349901B
(es)
|
2011-01-13 |
2017-08-18 |
Regeneron Pharma |
Uso de un antagonista de factor de crecimiento endotelial vascular para tratar transtornos oculares angiogenicos.
|
EP2691112B1
(en)
|
2011-03-31 |
2018-05-23 |
Merck Sharp & Dohme Corp. |
Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
|
WO2012149197A2
(en)
|
2011-04-27 |
2012-11-01 |
Abbott Laboratories |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
EP2714738B1
(en)
|
2011-05-24 |
2018-10-10 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
TWI527590B
(zh)
*
|
2011-06-17 |
2016-04-01 |
艾瑞斯貿易公司 |
Fgf-18之凍乾調配物
|
EP2735315B1
(en)
|
2011-07-19 |
2019-10-02 |
Chugai Seiyaku Kabushiki Kaisha |
Stable protein-containing preparation containing argininamide or valinamide
|
US20130022551A1
(en)
|
2011-07-22 |
2013-01-24 |
Trustees Of Boston University |
DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
|
AR087305A1
(es)
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
GB201117233D0
(en)
|
2011-10-05 |
2011-11-16 |
Stabilitech Ltd |
Stabilisation of polypeptides
|
CN117018187A
(zh)
|
2011-10-14 |
2023-11-10 |
霍夫曼-拉罗奇有限公司 |
Her2二聚化抑制剂帕妥珠单抗的用途和包含her2二聚化抑制剂帕妥珠单抗的制品
|
SG11201401360XA
(en)
*
|
2011-10-25 |
2014-05-29 |
Onclave Therapeutics Ltd |
Antibody formulations and methods
|
WO2013091903A1
(en)
|
2011-12-22 |
2013-06-27 |
Novo Nordisk A/S |
Anti-crac channel antibodies
|
US20130195851A1
(en)
|
2011-12-23 |
2013-08-01 |
Genentech, Inc. |
Articles of manufacture and methods for co-administration of antibodies
|
CN102512384B
(zh)
*
|
2011-12-29 |
2014-11-26 |
嘉和生物药业有限公司 |
一种冻干剂型蛋白组合物及其制备方法
|
HUE045445T2
(hu)
|
2012-03-13 |
2019-12-30 |
Hoffmann La Roche |
Kombinált terápia petefészekrák kezelésére
|
WO2013148315A1
(en)
|
2012-03-27 |
2013-10-03 |
Genentech, Inc. |
Diagnosis and treatments relating to her3 inhibitors
|
WO2013158273A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Methods to modulate c-terminal lysine variant distribution
|
WO2013158279A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Protein purification methods to reduce acidic species
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
US20140004131A1
(en)
|
2012-05-04 |
2014-01-02 |
Novartis Ag |
Antibody formulation
|
SG10201709555SA
(en)
*
|
2012-05-18 |
2017-12-28 |
Genentech Inc |
High-concentration monoclonal antibody formulations
|
US9249182B2
(en)
|
2012-05-24 |
2016-02-02 |
Abbvie, Inc. |
Purification of antibodies using hydrophobic interaction chromatography
|
US20140017318A1
(en)
*
|
2012-07-10 |
2014-01-16 |
Kevin O'Connell |
Method to produce a medicinal product comprising a biologically active protein and the resulting product
|
KR20180011356A
(ko)
|
2012-08-07 |
2018-01-31 |
제넨테크, 인크. |
교모세포종의 치료를 위한 조합 요법
|
FR2994390B1
(fr)
|
2012-08-10 |
2014-08-15 |
Adocia |
Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
|
US9592297B2
(en)
|
2012-08-31 |
2017-03-14 |
Bayer Healthcare Llc |
Antibody and protein formulations
|
US8613919B1
(en)
|
2012-08-31 |
2013-12-24 |
Bayer Healthcare, Llc |
High concentration antibody and protein formulations
|
US9206390B2
(en)
|
2012-09-02 |
2015-12-08 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
WO2014045081A1
(en)
|
2012-09-18 |
2014-03-27 |
Adocia |
Stable pharmaceutical composition, comprising an aqueous solution of an antibody-derived therapeutically active protein
|
EP2897587A1
(en)
|
2012-09-18 |
2015-07-29 |
Adocia |
Stable pharmaceutical composition, comprising an aqueous solution of an antibody-derived therapeutically active protein
|
AU2013334493B2
(en)
|
2012-10-26 |
2018-11-29 |
The University Of Queensland |
Use of endocytosis inhibitors and antibodies for cancer therapy
|
JP6339578B2
(ja)
*
|
2012-10-31 |
2018-06-06 |
タケダ・ゲー・エム・ベー・ハーTakeda GmbH |
Gm−csf中和化合物を含む凍結乾燥製剤
|
BR112015014853A2
(pt)
*
|
2012-12-21 |
2017-08-22 |
Glenmark Pharmaceuticals Sa |
Formulação farmacêutica, formulação farmacêutica liofilizada, uso de uma formulação farmacêutica e artigo de manufatura
|
EP2830651A4
(en)
|
2013-03-12 |
2015-09-02 |
Abbvie Inc |
HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
|
US8921526B2
(en)
|
2013-03-14 |
2014-12-30 |
Abbvie, Inc. |
Mutated anti-TNFα antibodies and methods of their use
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
US9499614B2
(en)
|
2013-03-14 |
2016-11-22 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
|
WO2014140361A1
(en)
*
|
2013-03-15 |
2014-09-18 |
Takeda Gmbh |
Formulation of an antibody and use thereof
|
MX2015013163A
(es)
|
2013-03-15 |
2016-04-04 |
Zyngenia Inc |
Complejos multiespecificos multivalente y monovalentes y sus usos.
|
EP2991672A1
(en)
|
2013-04-30 |
2016-03-09 |
Novo Nordisk A/S |
Novel administration regime
|
JP6530391B2
(ja)
|
2013-07-23 |
2019-06-12 |
バイオコン・リミテッド |
Cd6結合パートナーの使用およびそれに基づく方法
|
MX2016002177A
(es)
|
2013-08-30 |
2016-06-28 |
Takeda Gmbh |
Anticuerpos neutralizantes de gm-csf para usarse en el tratamiento de artritis reumatoide o como analgesicos.
|
AR097762A1
(es)
|
2013-09-27 |
2016-04-13 |
Intervet Int Bv |
Formulaciones secas de vacunas que son estables a temperatura ambiente
|
EP3052640A2
(en)
|
2013-10-04 |
2016-08-10 |
AbbVie Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
US20150139988A1
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
CN106163567B
(zh)
|
2013-11-21 |
2021-06-11 |
根马布股份公司 |
抗体-药物缀合物冻干制剂
|
CN104707146B
(zh)
*
|
2013-12-16 |
2019-04-16 |
浙江海正药业股份有限公司 |
一种含有阿达木单抗的药物组合物
|
EP3104882B1
(en)
|
2014-02-14 |
2019-06-05 |
Centrose, Llc |
Extracellular targeted drug conjugates
|
CN103893135B
(zh)
*
|
2014-03-28 |
2017-01-11 |
中国医学科学院输血研究所 |
一种人血浆蛋白c的冻干稳定剂组合物及其用途
|
GB201406569D0
(en)
|
2014-04-11 |
2014-05-28 |
Stabilitech Ltd |
Vaccine compositions
|
US11058768B2
(en)
|
2014-04-16 |
2021-07-13 |
Biocon Ltd. |
Stable protein formulations comprising a molar excess of sorbitol
|
WO2015169742A1
(en)
|
2014-05-07 |
2015-11-12 |
Takeda Gmbh |
Liquid formulation comprising gm-csf neutralizing compound
|
US10206973B2
(en)
*
|
2014-05-28 |
2019-02-19 |
Nono Inc. |
Chloride salt of TAT-NR2B9c
|
KR102366644B1
(ko)
|
2014-05-30 |
2022-02-22 |
상하이 헨리우스 바이오테크, 인크. |
항-표피 성장 인자 수용체 (egfr) 항체
|
CN114057857A
(zh)
|
2014-06-20 |
2022-02-18 |
豪夫迈·罗氏有限公司 |
基于chagasin的支架组合物、方法和应用
|
EP4285930A3
(en)
*
|
2014-06-26 |
2024-02-28 |
Amgen Inc. |
Protein formulations
|
WO2016019969A1
(en)
|
2014-08-08 |
2016-02-11 |
Ludwig-Maximilians-Universität München |
Subcutaneously administered bispecific antibodies for use in the treatment of cancer
|
WO2016037947A1
(en)
|
2014-09-10 |
2016-03-17 |
F. Hoffmann-La Roche Ag |
Galactoengineered immunoglobulin 1 antibodies
|
RU2020126237A
(ru)
|
2014-11-19 |
2020-12-01 |
Аксон Ньюросайенс Се |
Гуманизированные тау-антитела при болезни альцгеймера
|
WO2016123329A2
(en)
|
2015-01-28 |
2016-08-04 |
Genentech, Inc. |
Gene expression markers and treatment of multiple sclerosis
|
CN114456272A
(zh)
|
2015-04-03 |
2022-05-10 |
优瑞科生物技术公司 |
靶向afp肽/mhc复合体的构建体及其用途
|
WO2016169454A1
(zh)
|
2015-04-21 |
2016-10-27 |
舒泰神(北京)生物制药股份有限公司 |
一种神经生长因子组合物及注射粉剂
|
EP3287139B1
(en)
|
2015-04-21 |
2021-08-11 |
Staidson (Beijing) Biopharmaceuticals Co., Ltd. |
Nerve growth factor composition and injection powder
|
EP3286227A2
(en)
|
2015-04-24 |
2018-02-28 |
F. Hoffmann-La Roche AG |
Multispecific antigen-binding proteins
|
DK3313879T3
(da)
|
2015-06-24 |
2022-03-14 |
Hoffmann La Roche |
Anti-transferrinreceptor-antistoffer med tilpasset affinitet
|
CN107922507B
(zh)
|
2015-08-18 |
2022-04-05 |
瑞泽恩制药公司 |
抗pcsk9抑制性抗体用来治疗接受脂蛋白单采的高脂血症患者
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
KR20180054864A
(ko)
|
2015-10-02 |
2018-05-24 |
에프. 호프만-라 로슈 아게 |
이중특이성 항-인간 cd20/인간 트랜스페린 수용체 항체 및 사용 방법
|
WO2017062682A2
(en)
|
2015-10-06 |
2017-04-13 |
Genentech, Inc. |
Method for treating multiple sclerosis
|
DK3384049T3
(da)
|
2015-12-03 |
2023-10-02 |
Regeneron Pharma |
Fremgangsmåder til associering af genetiske varianter med et klinisk resultat hos patienter, der lider af aldersrelateret makuladegeneration behandlet med anti-VEGF
|
MX2018008545A
(es)
|
2016-01-12 |
2018-12-19 |
Intron Biotechnology Inc |
Composicion antibacteriana y metodo para tratar infecciones por estafilococos con la composicion antibacteriana.
|
RU2708393C1
(ru)
*
|
2016-01-12 |
2019-12-06 |
Интрон Байотекнолоджи, Инк. |
Лиофилизированные композиции антибактериального белка
|
EP3402465B1
(en)
|
2016-01-13 |
2024-03-13 |
Genmab A/S |
Formulation for antibody and drug conjugate thereof
|
JP2019517991A
(ja)
|
2016-03-01 |
2019-06-27 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
低減したadcpを有するオビヌツズマブ及びリツキシマブ変異体
|
US11297828B2
(en)
|
2016-03-14 |
2022-04-12 |
The Regents Of The University Of Michigan |
Surface tension mediated lyo-processing technique for preservation of biologics
|
MX2018013683A
(es)
|
2016-05-10 |
2019-06-17 |
Genentech Inc |
Métodos para disminuir los enlaces de trisulfuro durante la producción recombinante de polipéptidos.
|
MX2018014916A
(es)
*
|
2016-06-01 |
2019-07-18 |
Servier Ip Uk Ltd |
Formulaciones de oxido de polialquileno-asparaginasa y metodos de preparacion y uso del mismo.
|
GB201610198D0
(en)
|
2016-06-10 |
2016-07-27 |
Ucb Biopharma Sprl |
Anti-ige antibodies
|
JP2019534858A
(ja)
|
2016-09-09 |
2019-12-05 |
ジェネンテック, インコーポレイテッド |
Frizzledの選択的ペプチド阻害剤
|
BR112019005129A2
(pt)
|
2016-09-16 |
2019-06-04 |
Shanghai Henlius Biotech Inc |
anticorpos anti-pd-1
|
US11351256B2
(en)
*
|
2016-10-07 |
2022-06-07 |
Regeneron Pharmaceuticals, Inc. |
Room temperature stable lyophilized protein
|
JP7071974B2
(ja)
|
2016-10-21 |
2022-05-19 |
バイオコン・リミテッド |
モノクローナル抗体および狼瘡の処置のための使用の方法
|
EP3541414A4
(en)
|
2016-11-21 |
2020-11-11 |
OBI Pharma, Inc. |
CONJUGATE BIOLOGICAL MOLECULES, PHARMACEUTICAL COMPOSITIONS AND PROCESSES
|
CA3047175A1
(en)
|
2016-12-15 |
2018-06-21 |
Talengen International Limited |
Method for mitigating heart disease
|
EP3556388A4
(en)
|
2016-12-15 |
2020-07-08 |
Talengen International Limited |
METHOD FOR PREVENTING AND TREATING PATHOLOGICAL KIDNEY DAMAGE
|
WO2018107686A1
(zh)
|
2016-12-15 |
2018-06-21 |
深圳瑞健生命科学研究院有限公司 |
一种治疗动脉粥样硬化及其并发症的方法
|
JP7175270B2
(ja)
|
2016-12-15 |
2022-11-18 |
タレンゲン インターナショナル リミテッド |
グルカゴン、インスリンを正常なバランスに戻らせる方法
|
TW201828976A
(zh)
|
2016-12-15 |
2018-08-16 |
大陸商深圳瑞健生命科學硏究院有限公司 |
纖溶酶原在製備預防和治療骨質疏鬆及其相關病症的藥物中的用途和包含纖溶酶原用於預防或治療骨質疏鬆的藥劑
|
US11154595B2
(en)
|
2016-12-15 |
2021-10-26 |
Talengen International Limited |
Method for preventing and treating pulmonary fibrosis
|
CA3047181A1
(en)
|
2016-12-15 |
2018-06-21 |
Talengen International Limited |
Method and drug for preventing and treating obesity
|
CA3046092A1
(en)
|
2016-12-28 |
2018-07-05 |
Genentech, Inc. |
Treatment of advanced her2 expressing cancer
|
WO2018132597A1
(en)
|
2017-01-12 |
2018-07-19 |
Eureka Therapeutics, Inc. |
Constructs targeting histone h3 peptide/mhc complexes and uses thereof
|
KR20200113292A
(ko)
|
2017-01-17 |
2020-10-06 |
제넨테크, 인크. |
피하 her2 항체 제형
|
US20210330801A1
(en)
|
2017-03-02 |
2021-10-28 |
Cadila Healthcare Limited |
Novel protein drug conjugate formulation
|
US11077189B2
(en)
|
2017-03-02 |
2021-08-03 |
Genentech Inc. |
Adjuvant treatment of HER2-positive breast cancer
|
US11447564B2
(en)
|
2017-04-26 |
2022-09-20 |
Eureka Therapeutics, Inc. |
Constructs specifically recognizing glypican 3 and uses thereof
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
BR112019022873A8
(pt)
|
2017-05-02 |
2023-04-11 |
Merck Sharp & Dohme |
Formulação, e, vaso ou dispositivo de injeção.
|
GB2562241B
(en)
|
2017-05-08 |
2022-04-06 |
Stabilitech Biopharma Ltd |
Vaccine compositions
|
MY195465A
(en)
*
|
2017-05-16 |
2023-01-25 |
Jiangsu Hengrui Medicine Co |
PD-L1 Antibody Pharmaceutical Composition and use Thereof
|
JP7438942B2
(ja)
|
2017-10-30 |
2024-02-27 |
エフ. ホフマン-ラ ロシュ アーゲー |
単一特異性抗体から多重特異性抗体をインビボ生成させるための方法
|
US11642397B2
(en)
|
2017-12-15 |
2023-05-09 |
Talengen International Limited |
Method and drug for preventing or treating osteoarthritis
|
AU2019244481A1
(en)
|
2018-03-28 |
2020-10-01 |
Axon Neuroscience Se |
Antibody-based methods of detecting and treating Alzheimer's disease
|
CA3095186A1
(en)
|
2018-04-13 |
2019-10-17 |
Genentech, Inc. |
Stable anti-cd79b immunoconjugate formulations
|
KR20210021299A
(ko)
|
2018-05-10 |
2021-02-25 |
리제너론 파아마슈티컬스, 인크. |
고농도 vegf 수용체 융합 단백질 함유 제제
|
US11519020B2
(en)
|
2018-05-25 |
2022-12-06 |
Regeneron Pharmaceuticals, Inc. |
Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
|
US10335464B1
(en)
|
2018-06-26 |
2019-07-02 |
Novo Nordisk A/S |
Device for titrating basal insulin
|
WO2020061374A1
(en)
|
2018-09-20 |
2020-03-26 |
Mandalmed, Inc. |
Methods and compositions for preventing, treating, and reversing liver fibrosis
|
WO2020089743A1
(en)
*
|
2018-11-02 |
2020-05-07 |
Cadila Healthcare Limited |
Pharmaceutical composition of pegylated l-asparaginase
|
EP3880714A4
(en)
|
2018-11-16 |
2022-07-20 |
Memorial Sloan Kettering Cancer Center |
ANTIBODIES TO MUCIN-16 AND METHODS OF USE THEREOF
|
GB201820554D0
(en)
|
2018-12-17 |
2019-01-30 |
Univ Oxford Innovation Ltd |
BTLA antibodies
|
GB201820547D0
(en)
|
2018-12-17 |
2019-01-30 |
Oxford Univ Innovation |
Modified antibodies
|
CN111375057A
(zh)
*
|
2018-12-28 |
2020-07-07 |
上海复宏汉霖生物技术股份有限公司 |
一种包含抗Her2单克隆抗体的药物配制剂
|
CN112121150A
(zh)
*
|
2019-06-24 |
2020-12-25 |
杭州生物医药创新研究中心 |
一种成纤维细胞生长因子10冻干粉
|
CN112300279A
(zh)
|
2019-07-26 |
2021-02-02 |
上海复宏汉霖生物技术股份有限公司 |
针对抗cd73抗体和变体的方法和组合物
|
EP3808777A1
(en)
|
2019-10-16 |
2021-04-21 |
Glenmark Specialty S.A. |
Stable liquid antibody formulations
|
CN114867488A
(zh)
|
2020-01-17 |
2022-08-05 |
泰伦基国际有限公司 |
一种治疗神经损伤及其相关病症的方法
|
TWI787732B
(zh)
|
2020-02-06 |
2022-12-21 |
大陸商深圳瑞健生命科學研究院有限公司 |
一種預防和治療多發性硬化症的方法和藥物
|
KR20220148209A
(ko)
|
2020-02-28 |
2022-11-04 |
상하이 헨리우스 바이오테크, 인크. |
항cd137 작제물 및 그 용도
|
KR20220145859A
(ko)
|
2020-02-28 |
2022-10-31 |
상하이 헨리우스 바이오테크, 인크. |
항cd137 작제물, 다중 특이적 항체 및 그 용도
|
US20230143354A1
(en)
|
2020-03-24 |
2023-05-11 |
Talengen International Limited |
Method and drug for treating parkinson's disease
|
CA3176941A1
(en)
|
2020-03-24 |
2021-09-30 |
Talengen International Limited |
Method and medicine for treating huntington's disease
|
US20230346897A1
(en)
|
2020-03-24 |
2023-11-02 |
Talengen International Limited |
Method and drug for promoting degradation of misfolded protein and aggregate thereof
|
CN115666626A
(zh)
|
2020-03-24 |
2023-01-31 |
泰伦基国际有限公司 |
一种治疗阿尔茨海默病的方法和药物
|
WO2021238886A1
(en)
|
2020-05-27 |
2021-12-02 |
Staidson (Beijing) Biopharmaceuticals Co., Ltd. |
Antibodies specifically recognizing nerve growth factor and uses thereof
|
MX2022015376A
(es)
|
2020-06-02 |
2023-04-14 |
Dynamicure Biotechnology Llc |
Construcciones anti grupo de diferenciacion 93 (cd93) y usos de las mismas.
|
CN116529260A
(zh)
|
2020-06-02 |
2023-08-01 |
当康生物技术有限责任公司 |
抗cd93构建体及其用途
|
GB202008860D0
(en)
|
2020-06-11 |
2020-07-29 |
Univ Oxford Innovation Ltd |
BTLA antibodies
|
AU2021288637A1
(en)
*
|
2020-06-12 |
2023-01-19 |
Ichnos Sciences SA |
Antibody formulation diluent
|
CN113827717A
(zh)
*
|
2020-06-23 |
2021-12-24 |
三生国健药业(上海)股份有限公司 |
抗her2单克隆抗体冻干制剂及制备方法
|
IL299747A
(en)
|
2020-07-10 |
2023-03-01 |
Shanghai Jemincare Pharmaceutical Co Ltd |
Transgenic antibody against IGE and its application
|
IL300121A
(en)
|
2020-07-29 |
2023-03-01 |
Dynamicure Biotechnology Llc |
Anti-cd93 constructs and uses thereof
|
JP2023537751A
(ja)
|
2020-08-14 |
2023-09-05 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
オクレリズマブで多発性硬化症を治療するための方法
|
CN114246944A
(zh)
*
|
2020-09-24 |
2022-03-29 |
盛禾(中国)生物制药有限公司 |
一种双特异性抗体的药物组合物及其用途
|
CN112684177A
(zh)
*
|
2020-12-17 |
2021-04-20 |
北京维德维康生物技术有限公司 |
一种乳品多因子快速检测试剂盒及其检测方法
|
US20240141048A1
(en)
|
2021-03-05 |
2024-05-02 |
Dynamicure Biotechnology Llc |
Anti-vista constructs and uses thereof
|
JP2024511424A
(ja)
|
2021-03-25 |
2024-03-13 |
ダイナミキュア バイオテクノロジー エルエルシー |
抗igfbp7構築物およびその使用
|
EP4355785A1
(en)
|
2021-06-17 |
2024-04-24 |
Amberstone Biosciences, Inc. |
Anti-cd3 constructs and uses thereof
|
WO2023283611A1
(en)
|
2021-07-08 |
2023-01-12 |
Staidson Biopharma Inc. |
Antibodies specifically recognizing tnfr2 and uses thereof
|
CN115812082A
(zh)
|
2021-07-14 |
2023-03-17 |
舒泰神(北京)生物制药股份有限公司 |
特异性识别cd40的抗体及其应用
|
WO2023019556A1
(zh)
*
|
2021-08-20 |
2023-02-23 |
齐鲁制药有限公司 |
一种高浓度抗her2的抗体制剂及其用途
|
WO2024020407A1
(en)
|
2022-07-19 |
2024-01-25 |
Staidson Biopharma Inc. |
Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof
|
WO2024037633A2
(en)
|
2022-08-19 |
2024-02-22 |
Evive Biotechnology (Shanghai) Ltd |
Formulations comprising g-csf and uses thereof
|
WO2024054929A1
(en)
|
2022-09-07 |
2024-03-14 |
Dynamicure Biotechnology Llc |
Anti-vista constructs and uses thereof
|
CN115746082A
(zh)
*
|
2022-12-02 |
2023-03-07 |
大连工业大学 |
一种调控糖基化鳕鱼蛋白结构的方法及其在制备高内相乳液中的应用
|